ticlopidine has been researched along with Shock, Cardiogenic in 19 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far." | 7.78 | Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "The two new drugs prasugrel and ticagrelor were included in the current guidelines for the treatment of patients with acute coronary syndrome." | 4.90 | [Dual platelet inhibitors in intensive care units]. ( Delle Karth, G; Siller-Matula, JM, 2014) |
| "Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far." | 3.78 | Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. ( Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6." | 1.38 | The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012) |
| "Stent thrombosis is not unusual in a post-operative setting." | 1.38 | Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. ( Agnani, S; Akkus, NI; Rajpal, S, 2012) |
| "Cardiogenic shock was present in 45%, and distal left main coronary artery disease was present in 71% of patients." | 1.37 | Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. ( El-Omar, M; Imola, F; Mamas, MA; Manzoli, A; Pappalardo, A; Prati, F; Ramazzotti, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanic, V | 1 |
| Vollrath, M | 1 |
| Penko, M | 1 |
| Markota, A | 1 |
| Kompara, G | 1 |
| Kanic, Z | 1 |
| Almalla, M | 1 |
| Schröder, J | 1 |
| Hennings, V | 1 |
| Marx, N | 1 |
| Hoffmann, R | 1 |
| Siller-Matula, JM | 1 |
| Delle Karth, G | 1 |
| Orban, M | 4 |
| Mayer, K | 2 |
| Morath, T | 2 |
| Bernlochner, I | 2 |
| Hadamitzky, M | 2 |
| Braun, S | 2 |
| Schulz, S | 2 |
| Hoppmann, P | 2 |
| Hausleiter, J | 4 |
| Tiroch, K | 2 |
| Mehilli, J | 2 |
| Schunkert, H | 2 |
| Massberg, S | 3 |
| Laugwitz, KL | 2 |
| Sibbing, D | 3 |
| Kastrati, A | 3 |
| Limbourg, T | 1 |
| Neumann, FJ | 1 |
| Ferenc, M | 1 |
| Olbrich, HG | 1 |
| Richardt, G | 1 |
| Hennersdorf, M | 1 |
| Empen, K | 1 |
| Fuernau, G | 1 |
| Desch, S | 1 |
| Eitel, I | 1 |
| Hambrecht, R | 1 |
| Pöss, J | 1 |
| Schneider, S | 1 |
| Schuler, G | 1 |
| Werdan, K | 1 |
| Zeymer, U | 1 |
| Thiele, H | 1 |
| Gogorishvili, I | 1 |
| Archvadze, A | 1 |
| Kipiani, V | 1 |
| Kipshidze, N | 1 |
| Ergelen, M | 1 |
| Uyarel, H | 1 |
| Osmonov, D | 1 |
| Ayhan, E | 1 |
| Akkaya, E | 1 |
| Soylu, O | 1 |
| Orhan, AL | 1 |
| Sayar, N | 1 |
| Bozbay, M | 1 |
| Turer, A | 1 |
| Yildirim, E | 1 |
| Yekeler, I | 1 |
| Osmancik, P | 1 |
| Jirmar, R | 1 |
| Hulikova, K | 1 |
| Peroutka, Z | 1 |
| Pompachova, A | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Pappalardo, A | 1 |
| Mamas, MA | 1 |
| Imola, F | 1 |
| Ramazzotti, V | 1 |
| Manzoli, A | 1 |
| Prati, F | 1 |
| El-Omar, M | 1 |
| Koul, S | 1 |
| Smith, JG | 1 |
| Scherstén, F | 1 |
| James, S | 1 |
| Lagerqvist, B | 1 |
| Erlinge, D | 1 |
| Yan, BP | 1 |
| Ajani, AE | 1 |
| Clark, DJ | 1 |
| Duffy, SJ | 1 |
| Andrianopoulos, N | 1 |
| Brennan, AL | 1 |
| Loane, P | 1 |
| Reid, CM | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Gore, JM | 1 |
| Goldberg, RJ | 1 |
| Leone, AM | 1 |
| Sgueglia, GA | 1 |
| Porto, I | 1 |
| Niccoli, G | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| De Caterina, AR | 1 |
| Buffon, A | 1 |
| Mazzari, MA | 1 |
| Mongiardo, R | 1 |
| Rebuzzi, AG | 1 |
| Crea, F | 1 |
| Akkus, NI | 1 |
| Rajpal, S | 1 |
| Agnani, S | 1 |
| Riegger, J | 1 |
| Joner, M | 1 |
| Tada, T | 1 |
| Okrojek, R | 1 |
| Katayama, T | 1 |
| Nakashima, H | 1 |
| Takagi, C | 1 |
| Honda, Y | 1 |
| Suzuki, S | 1 |
| Yano, K | 1 |
| Karthikeyan, G | 1 |
1 review available for ticlopidine and Shock, Cardiogenic
| Article | Year |
|---|---|
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Hum | 2014 |
1 trial available for ticlopidine and Shock, Cardiogenic
| Article | Year |
|---|---|
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myo | 2016 |
17 other studies available for ticlopidine and Shock, Cardiogenic
| Article | Year |
|---|---|
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel | 2018 |
Long-term outcome after angiographically proven coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E | 2013 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh | 2014 |
The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Hypothermia, I | 2015 |
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol | 2008 |
Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Incid | 2010 |
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Case-Control S | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction.
Topics: Aged; Angioplasty; Bundle-Branch Block; Clopidogrel; Confidence Intervals; Coronary Artery Disease; | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazi | 2012 |
Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock.
Topics: Angioplasty, Balloon; Aspirin; C-Reactive Protein; Cholesterol; Electrocardiography; Hormones; Human | 2005 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggreg | 2006 |